Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coapt Systems Launches Hydrelle
Coapt Systems has launched Hydrelle, a new FDA-approved hyaluronic acid-based dermal filler, for the treatment of facial wrinkles. Hydrelle has been formulated with an anesthetic (lidocaine) for greater
Coapt Systems has launched Hydrelle, a new FDA-approved hyaluronic acid-based dermal filler, for the treatment of facial wrinkles. Hydrelle has been formulated with an anesthetic (lidocaine) for greater
OXiGENE, a clinical-stage biopharmaceutical company developing therapeutics to treat cancer and eye diseases, is all set to acquire all of the equity of Symphony ViDA, in exchange for
Celtic Pharma Holdings Advisors (CPHA), the advisor to the second Celtic pharma fund, Celtic Pharma Holdings II LP (CP2), would invest in a majority shareholding in Novacta Biosystems
Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx’s BL-1040. Its a potential treatment for preventing pathological cardiac remodeling, following acute myocardial infarction
Proteome Sciences and Millipore have signed an exclusive license agreement to develop new products that will help to advance the study of Alzheimer’s disease. Under the terms of
Eli Lilly has received a fourth approval from FDA for Alimta (pemetrexed for injection). The latest approval is for Alimta as a maintenance therapy for locally advanced or
MorphoSys has announced that Novartis has committed to a ten-year term of the strategic alliance, originally signed in December 2007. The decision was based on the successful achievement
The US Patent and Trademark Office (PTO) is re-examining two currently issued US patents owned by the Institute Pasteur and the Universite Pierre et Marie Curie, and licensed
Novartis has delivered the 250 millionth treatment of Coartem, an artemisinin-based combination therapy (ACT) for the treatment of malaria. The 250,000,000th treatment was delivered to healthcare clinic in
Actelion’ pediatric dispersible formulation of Tracleer (bosentan) for the treatment of pulmonary arterial hypertension (PAH) in children, has been approved in the EU. Tracleer is an oral, dual